Concepts (201)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Stroke | 25 | 2026 | 1061 | 2.100 |
Why?
|
| Cerebral Hemorrhage | 11 | 2024 | 158 | 1.510 |
Why?
|
| Brain Ischemia | 9 | 2022 | 266 | 0.910 |
Why?
|
| Telemedicine | 6 | 2024 | 526 | 0.670 |
Why?
|
| Kentucky | 15 | 2024 | 29 | 0.590 |
Why?
|
| Antibodies, Monoclonal | 1 | 2024 | 981 | 0.550 |
Why?
|
| Ohio | 13 | 2024 | 85 | 0.500 |
Why?
|
| Fibrinolytic Agents | 5 | 2022 | 182 | 0.350 |
Why?
|
| Health Status Disparities | 4 | 2024 | 282 | 0.330 |
Why?
|
| Tissue Plasminogen Activator | 4 | 2022 | 104 | 0.320 |
Why?
|
| Emergency Medical Services | 4 | 2018 | 352 | 0.310 |
Why?
|
| Subarachnoid Hemorrhage | 2 | 2024 | 71 | 0.310 |
Why?
|
| Hypertension | 4 | 2026 | 1356 | 0.300 |
Why?
|
| Stroke Rehabilitation | 2 | 2020 | 65 | 0.300 |
Why?
|
| Aged, 80 and over | 16 | 2024 | 6797 | 0.300 |
Why?
|
| Hyperglycemia | 2 | 2014 | 234 | 0.290 |
Why?
|
| Sex Factors | 7 | 2020 | 1356 | 0.290 |
Why?
|
| Veterans | 5 | 2024 | 1763 | 0.280 |
Why?
|
| Aged | 27 | 2024 | 21025 | 0.270 |
Why?
|
| Brain | 2 | 2012 | 3175 | 0.260 |
Why?
|
| Middle Aged | 26 | 2026 | 28601 | 0.250 |
Why?
|
| Blood Pressure | 3 | 2024 | 1345 | 0.240 |
Why?
|
| Mushroom Bodies | 1 | 2005 | 11 | 0.230 |
Why?
|
| Intracranial Aneurysm | 2 | 2018 | 89 | 0.210 |
Why?
|
| Humans | 45 | 2026 | 131163 | 0.210 |
Why?
|
| Risk Factors | 13 | 2026 | 11074 | 0.210 |
Why?
|
| Incidence | 8 | 2026 | 3360 | 0.200 |
Why?
|
| Apolipoprotein E2 | 2 | 2014 | 16 | 0.200 |
Why?
|
| Migraine Disorders | 1 | 2024 | 59 | 0.200 |
Why?
|
| Alzheimer Disease | 2 | 2024 | 878 | 0.200 |
Why?
|
| Male | 32 | 2026 | 64957 | 0.200 |
Why?
|
| Cerebrovascular Disorders | 1 | 2024 | 111 | 0.190 |
Why?
|
| Glucosephosphate Dehydrogenase Deficiency | 1 | 2023 | 13 | 0.190 |
Why?
|
| Amyloid beta-Peptides | 1 | 2024 | 229 | 0.190 |
Why?
|
| Neurology | 1 | 2024 | 116 | 0.190 |
Why?
|
| Opiate Alkaloids | 1 | 2022 | 4 | 0.180 |
Why?
|
| Axons | 1 | 2005 | 386 | 0.180 |
Why?
|
| Emergency Service, Hospital | 6 | 2022 | 1224 | 0.180 |
Why?
|
| Female | 30 | 2026 | 70963 | 0.180 |
Why?
|
| Endocarditis | 1 | 2023 | 102 | 0.180 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2017 | 744 | 0.170 |
Why?
|
| Cocaine | 1 | 2022 | 211 | 0.160 |
Why?
|
| Poverty | 1 | 2024 | 462 | 0.160 |
Why?
|
| Drug Resistant Epilepsy | 1 | 2024 | 287 | 0.160 |
Why?
|
| Recurrence | 1 | 2024 | 1489 | 0.160 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2024 | 570 | 0.150 |
Why?
|
| Drosophila Proteins | 1 | 2005 | 718 | 0.150 |
Why?
|
| Thrombolytic Therapy | 3 | 2022 | 191 | 0.150 |
Why?
|
| Education, Medical, Graduate | 1 | 2024 | 554 | 0.150 |
Why?
|
| Continuity of Patient Care | 1 | 2021 | 143 | 0.150 |
Why?
|
| Time Factors | 8 | 2024 | 6196 | 0.150 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2021 | 146 | 0.150 |
Why?
|
| Nuclear Proteins | 1 | 2005 | 1211 | 0.150 |
Why?
|
| Ischemic Attack, Transient | 1 | 2019 | 58 | 0.150 |
Why?
|
| Guideline Adherence | 2 | 2019 | 387 | 0.140 |
Why?
|
| Prospective Studies | 8 | 2017 | 6459 | 0.140 |
Why?
|
| Certification | 1 | 2019 | 71 | 0.140 |
Why?
|
| Deprescriptions | 1 | 2017 | 9 | 0.130 |
Why?
|
| Substance-Related Disorders | 1 | 2022 | 496 | 0.130 |
Why?
|
| Cerebral Arteries | 1 | 2018 | 81 | 0.130 |
Why?
|
| Regional Blood Flow | 1 | 2018 | 191 | 0.130 |
Why?
|
| Platelet Transfusion | 1 | 2017 | 55 | 0.130 |
Why?
|
| Patient Satisfaction | 1 | 2020 | 464 | 0.130 |
Why?
|
| Hospitals, Urban | 1 | 2017 | 97 | 0.130 |
Why?
|
| Troponin | 1 | 2017 | 69 | 0.120 |
Why?
|
| Case-Control Studies | 5 | 2016 | 3359 | 0.120 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2017 | 88 | 0.120 |
Why?
|
| Cerebral Angiography | 1 | 2017 | 106 | 0.120 |
Why?
|
| Epilepsy | 1 | 2024 | 876 | 0.120 |
Why?
|
| Triage | 1 | 2017 | 144 | 0.120 |
Why?
|
| Prevalence | 5 | 2024 | 2701 | 0.120 |
Why?
|
| Retrospective Studies | 11 | 2024 | 17753 | 0.120 |
Why?
|
| Post-Exposure Prophylaxis | 1 | 2015 | 11 | 0.120 |
Why?
|
| Amino Acid Metabolism, Inborn Errors | 1 | 2017 | 115 | 0.120 |
Why?
|
| Healthcare Disparities | 2 | 2021 | 523 | 0.120 |
Why?
|
| Glycoproteins | 1 | 2018 | 346 | 0.110 |
Why?
|
| Cerebral Ventricles | 1 | 2016 | 80 | 0.110 |
Why?
|
| Cerebral Small Vessel Diseases | 1 | 2015 | 10 | 0.110 |
Why?
|
| Gait Disorders, Neurologic | 1 | 2016 | 46 | 0.110 |
Why?
|
| Neurons | 1 | 2005 | 1979 | 0.110 |
Why?
|
| Urinary Incontinence | 1 | 2016 | 66 | 0.110 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2017 | 267 | 0.110 |
Why?
|
| Urban Population | 1 | 2017 | 287 | 0.110 |
Why?
|
| Genotype | 4 | 2014 | 2595 | 0.110 |
Why?
|
| Hyperlipidemias | 1 | 2016 | 185 | 0.110 |
Why?
|
| Atrial Fibrillation | 1 | 2022 | 738 | 0.100 |
Why?
|
| Adult | 9 | 2026 | 31282 | 0.100 |
Why?
|
| Practice Guidelines as Topic | 2 | 2017 | 1295 | 0.100 |
Why?
|
| Contrast Media | 1 | 2017 | 474 | 0.100 |
Why?
|
| Warfarin | 1 | 2014 | 121 | 0.100 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2014 | 3436 | 0.100 |
Why?
|
| Intracranial Hemorrhages | 1 | 2013 | 79 | 0.090 |
Why?
|
| White Matter | 1 | 2015 | 219 | 0.090 |
Why?
|
| Apolipoproteins E | 1 | 2013 | 187 | 0.090 |
Why?
|
| Anticonvulsants | 1 | 2015 | 363 | 0.090 |
Why?
|
| SOXF Transcription Factors | 1 | 2012 | 16 | 0.090 |
Why?
|
| Kidney Diseases | 1 | 2017 | 477 | 0.090 |
Why?
|
| Heart Diseases | 1 | 2017 | 499 | 0.090 |
Why?
|
| Sleep | 1 | 2015 | 381 | 0.090 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2015 | 245 | 0.090 |
Why?
|
| Treatment Outcome | 9 | 2017 | 12936 | 0.090 |
Why?
|
| Echocardiography | 1 | 2017 | 1125 | 0.080 |
Why?
|
| Peptides | 1 | 2013 | 708 | 0.080 |
Why?
|
| RNA, Long Noncoding | 1 | 2012 | 218 | 0.080 |
Why?
|
| Gene Expression Regulation | 1 | 2018 | 2323 | 0.080 |
Why?
|
| United States | 6 | 2024 | 12072 | 0.070 |
Why?
|
| Acute Kidney Injury | 1 | 2017 | 705 | 0.070 |
Why?
|
| Multivariate Analysis | 3 | 2017 | 1378 | 0.070 |
Why?
|
| United States Department of Veterans Affairs | 2 | 2024 | 729 | 0.070 |
Why?
|
| Age Factors | 3 | 2020 | 2825 | 0.070 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2017 | 1459 | 0.060 |
Why?
|
| Referral and Consultation | 2 | 2021 | 564 | 0.060 |
Why?
|
| Reperfusion Injury | 1 | 2006 | 107 | 0.060 |
Why?
|
| Cohort Studies | 3 | 2023 | 5063 | 0.050 |
Why?
|
| Larva | 1 | 2005 | 243 | 0.050 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2005 | 410 | 0.050 |
Why?
|
| Neuropeptides | 1 | 2005 | 106 | 0.050 |
Why?
|
| Headache Disorders | 1 | 2024 | 5 | 0.050 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 2005 | 101 | 0.050 |
Why?
|
| Animals, Genetically Modified | 1 | 2005 | 291 | 0.050 |
Why?
|
| Cardiovascular Diseases | 1 | 2017 | 2121 | 0.050 |
Why?
|
| Green Fluorescent Proteins | 1 | 2005 | 358 | 0.050 |
Why?
|
| Neurologists | 1 | 2024 | 25 | 0.050 |
Why?
|
| Embryonic Development | 1 | 2005 | 200 | 0.050 |
Why?
|
| Young Adult | 3 | 2026 | 10103 | 0.050 |
Why?
|
| Follow-Up Studies | 3 | 2017 | 5196 | 0.050 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 2005 | 254 | 0.050 |
Why?
|
| Odds Ratio | 2 | 2017 | 1211 | 0.050 |
Why?
|
| Phosphoproteins | 1 | 2005 | 448 | 0.050 |
Why?
|
| Educational Status | 1 | 2024 | 279 | 0.050 |
Why?
|
| Logistic Models | 2 | 2017 | 1797 | 0.050 |
Why?
|
| Social Class | 1 | 2024 | 214 | 0.050 |
Why?
|
| Severity of Illness Index | 3 | 2017 | 3061 | 0.050 |
Why?
|
| Demography | 1 | 2023 | 237 | 0.040 |
Why?
|
| Costs and Cost Analysis | 1 | 2022 | 151 | 0.040 |
Why?
|
| Environmental Exposure | 1 | 2024 | 298 | 0.040 |
Why?
|
| Fee-for-Service Plans | 1 | 2021 | 19 | 0.040 |
Why?
|
| Emotions | 1 | 2024 | 350 | 0.040 |
Why?
|
| Fellowships and Scholarships | 1 | 2024 | 327 | 0.040 |
Why?
|
| Occupational Health | 1 | 2021 | 43 | 0.040 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2005 | 950 | 0.040 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2021 | 37 | 0.040 |
Why?
|
| Animals | 4 | 2018 | 33912 | 0.040 |
Why?
|
| Rats | 2 | 2018 | 3370 | 0.040 |
Why?
|
| Aftercare | 1 | 2022 | 157 | 0.040 |
Why?
|
| Models, Biological | 1 | 2005 | 1371 | 0.040 |
Why?
|
| Drosophila melanogaster | 1 | 2005 | 789 | 0.040 |
Why?
|
| Recombinant Proteins | 2 | 2013 | 1319 | 0.040 |
Why?
|
| Stroke Volume | 1 | 2022 | 541 | 0.040 |
Why?
|
| Curriculum | 1 | 2024 | 798 | 0.040 |
Why?
|
| Hospitals | 1 | 2022 | 435 | 0.040 |
Why?
|
| Sex Distribution | 1 | 2019 | 318 | 0.030 |
Why?
|
| Rats, Inbred BN | 1 | 2018 | 16 | 0.030 |
Why?
|
| Basilar Artery | 1 | 2018 | 16 | 0.030 |
Why?
|
| Patient-Centered Care | 1 | 2020 | 236 | 0.030 |
Why?
|
| Ventricular Function, Left | 1 | 2022 | 549 | 0.030 |
Why?
|
| Rats, Long-Evans | 1 | 2018 | 95 | 0.030 |
Why?
|
| Patient Discharge | 1 | 2022 | 514 | 0.030 |
Why?
|
| Ligation | 1 | 2018 | 134 | 0.030 |
Why?
|
| Glasgow Coma Scale | 1 | 2018 | 200 | 0.030 |
Why?
|
| Intracranial Hemorrhage, Traumatic | 1 | 2017 | 10 | 0.030 |
Why?
|
| Ventriculostomy | 1 | 2017 | 34 | 0.030 |
Why?
|
| Health Care Costs | 1 | 2021 | 407 | 0.030 |
Why?
|
| Halogenation | 1 | 2017 | 7 | 0.030 |
Why?
|
| Registries | 1 | 2024 | 1634 | 0.030 |
Why?
|
| Microarray Analysis | 1 | 2018 | 222 | 0.030 |
Why?
|
| Anticoagulants | 1 | 2022 | 605 | 0.030 |
Why?
|
| Analgesics, Opioid | 1 | 2023 | 546 | 0.030 |
Why?
|
| Administration, Intravenous | 1 | 2017 | 173 | 0.030 |
Why?
|
| Patient Safety | 1 | 2021 | 443 | 0.030 |
Why?
|
| Communication | 1 | 2020 | 543 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2017 | 563 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2018 | 325 | 0.030 |
Why?
|
| Disease Models, Animal | 2 | 2018 | 4697 | 0.030 |
Why?
|
| Transcription Factors | 1 | 2005 | 2406 | 0.030 |
Why?
|
| Quality of Health Care | 1 | 2019 | 413 | 0.030 |
Why?
|
| Rats, Inbred WKY | 1 | 2015 | 43 | 0.030 |
Why?
|
| Rats, Inbred SHR | 1 | 2015 | 54 | 0.030 |
Why?
|
| Mortality | 1 | 2017 | 264 | 0.030 |
Why?
|
| Thrombocytopenia | 1 | 2017 | 223 | 0.030 |
Why?
|
| Time-to-Treatment | 1 | 2017 | 209 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2021 | 689 | 0.030 |
Why?
|
| Age of Onset | 1 | 2015 | 592 | 0.030 |
Why?
|
| Signal Transduction | 1 | 2006 | 4686 | 0.030 |
Why?
|
| National Institute of Neurological Disorders and Stroke (U.S.) | 1 | 2013 | 13 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2016 | 1483 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2016 | 1410 | 0.020 |
Why?
|
| Risk | 1 | 2014 | 726 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2018 | 2550 | 0.020 |
Why?
|
| Disease Progression | 1 | 2018 | 2200 | 0.020 |
Why?
|
| Mutation | 1 | 2005 | 6099 | 0.020 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2017 | 789 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2013 | 1173 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2013 | 1626 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2017 | 2065 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2017 | 3829 | 0.020 |
Why?
|
| Prognosis | 1 | 2017 | 4886 | 0.020 |
Why?
|
| Smoking | 1 | 2012 | 932 | 0.020 |
Why?
|
| Genome-Wide Association Study | 1 | 2012 | 1833 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2012 | 2833 | 0.010 |
Why?
|
| Child | 1 | 2022 | 26341 | 0.010 |
Why?
|